

**APPENDIX A**

**Claim Amendments**

1.-38. (Canceled)

39. (Currently amended) A method of treating neoplasms of lymphoid cells in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound selected from the group consisting of N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide [INN: PICLAMILAST], 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide), 3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-isopropyl-3H-purine [Research Code: V-11294A], N-[9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzo-diazepin-3(R)-yl]pyridine-4-carboxamide [Research Code: CI-1018], 3,7-dihydro-3-(4-chlorophenyl)-1-propyl-1H-purine-2,6-dione [INN: AROFYLLINE],

N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281],

N-(3,5-dichloropyridin-4-yl)-2-[5-fluoro-1-(4-fluorobenzyl)-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-343],

Tetrahydro-5-[4-methoxy-3-[(1S,2S,4R)-2-norbornyloxy]phenyl]-2(1H)-pyrimidone [INN: ATIZORAM];  
β-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanamide [Research Code: CDC-801],  
Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzo-furan-6-yl ester [INN: LIRIMILAST],

3,5-dichloro-4-[8-methoxy-2-(trifluoromethyl)quinolin-5-ylcarbox-amido]pyridine-1-oxide [Research Code: SCH-351591],

cis-4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast],

~~the compounds~~ a compound with the research `[[codes]]` code CDC-998, D-4396, IC-485, CC-1088 `[[and]]` or KW4490,  
~~or a pharmaceutically acceptable salt~~ and pharmaceutically acceptable salts thereof.

40. (Currently amended) A method for treating neoplasms of lymphoid cells in a mammal, [[including:]] comprising administering to said mammal therapeutically effective amounts of

(i) a compound selected from the group consisting of

N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-

methoxybenzamide [INN: PICLAMILAST],

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-

dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-

cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide),

3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-

isopropyl-3H-purine [Research Code: V-11294A],

N-[9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzo-diazepin-3(R)-yl]pyridine-4-carboxamide

[Research Code: CI-1018],

3,7-dihydro-3-(4-chlorophenyl)-1-propyl-1H-purine-2,6-dione

[INN: AROFYLLINE],

N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-

hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281],

N-(3,5-dichloropyridin-4-yl)-2-[5-fluoro-1-(4-fluorobenzyl)-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-343],  
Tetrahydro-5-[4-methoxy-3-[(1S,2S,4R)-2-norbornyloxy]phenyl]-2(1H)-pyrimidone [INN: ATIZORAM];  
 $\beta$ -[3-(cyclopentyloxy)-4-methoxyphenyl]-1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanamide [Research Code: CDC-801],  
Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzo-furan-6-yl ester [INN: LIRIMILAST],  
3,5-dichloro-4-[8-methoxy-2-(trifluoromethyl)quinolin-5-ylcarbox-amido]pyridine-1-oxide [Research Code: SCH-351591],  
cis-4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast],  
~~the compounds~~ a compound with the research [[codes]] code CDC-998, D-4396, IC-485, CC-1088 [[and]] or KW4490,  
~~or a pharmaceutically acceptable salt~~ and pharmaceutically acceptable salts thereof,  
and (ii) one or more differentiation inducing agents and/or an agent effective in raising intracellular concentrations of cAMP or a stable analogue thereof.

41. (Currently amended) A method for treating neoplasms of lymphoid cells in a mammal, [[including:]] comprising administering to said mammal therapeutically effective amounts of

(i) a compound selected from the group consisting of

N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-

methoxybenzamide [INN: PICLAMILAST],

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-

dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-

cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide),

3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-

isopropyl-3H-purine [Research Code: V-11294A],

N-[9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzo-diazepin-3(R)-yl]pyridine-4-carboxamide

[Research Code: CI-1018],

3,7-dihydro-3-(4-chlorophenyl)-1-propyl-1H-purine-2,6-dione

[INN: AROFYLLINE],

N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-

hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281],

N-(3,5-dichloropyridin-4-yl)-2-[5-fluoro-1-(4-fluorobenzyl)-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-343],  
Tetrahydro-5-[4-methoxy-3-[(1S,2S,4R)-2-norbornyloxy]phenyl]-2(1H)-pyrimidone [INN: ATIZORAM];  
 $\beta$ -[3-(cyclopentyloxy)-4-methoxyphenyl]-1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanamide [Research Code: CDC-801],  
Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzo-furan-6-yl ester [INN: LIRIMILAST],  
3,5-dichloro-4-[8-methoxy-2-(trifluoromethyl)quinolin-5-ylcarbox-amido]pyridine-1-oxide [Research Code: SCH-351591],  
cis-4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast],  
~~the compounds~~ a compound with the research [[codes]] code CDC-998, D-4396, IC-485, CC-1088 [[and]] or KW4490,  
~~or a pharmaceutically acceptable salt~~ and pharmaceutically acceptable salts thereof,  
and (ii) one or more differentiation inducing agents.

42. (Currently amended) A method for treating neoplasms of lymphoid cells in a mammal, [[including:]] comprising

administering to said mammal therapeutically effective amounts of

(i) a compound selected from the group consisting of

N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-

methoxybenzamide [INN: PICLAMILAST],

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-

dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-

cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-

pyrid-4-yl)-benzamide (Roflumilast-N-Oxide),

3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-

isopropyl-3H-purine [Research Code: V-11294A],

N-[9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzo-diazepin-3(R)-yl]pyridine-4-carboxamide

[Research Code: CI-1018],

3,7-dihydro-3-(4-chlorophenyl)-1-propyl-1H-purine-2,6-dione

[INN: AROFYLLINE],

N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-

hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281],

N-(3,5-dichloropyridin-4-yl)-2-[5-fluoro-1-(4-

fluorobenzyl)-1H-indol-3-yl]-2-oxoacetamide [Research Code:

AWD-12-343],

Tetrahydro-5-[4-methoxy-3-[(1S,2S,4R)-2-norbornyloxy]phenyl]-2(1H)-pyrimidone [INN: ATIZORAM];  
β-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanamide [Research Code: CDC-801],  
Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzo-furan-6-yl ester [INN: LIRIMILAST],  
3,5-dichloro-4-[8-methoxy-2-(trifluoromethyl)quinolin-5-ylcarbox-amido]pyridine-1-oxide [Research Code: SCH-351591],  
cis-4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast],  
~~the compounds~~ a compound with the research [[codes]] code CDC-998, D-4396, IC-485, CC-1088 [[and]] or KW4490,  
~~or a pharmaceutically acceptable salt and pharmaceutically acceptable salts thereof,~~  
and (ii) an agent effective in raising intracellular concentrations of cAMP or a stable analogue thereof.

43. (Canceled)

44. (Currently amended) [[A]] The method according to claim 39 ~~any of the claims 39, 40, 41 or 42,~~ wherein the

compound of component (i) is selected from the group consisting of

N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281],

cis-4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast],

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], [[and]]

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide),

~~or a pharmaceutically acceptable salt~~ and pharmaceutically acceptable salts thereof.

45. (Currently amended) [[A]] The method according to claim 39 ~~any of the claims 39, 40, 41 or 42~~, wherein the compound of component (i) is selected from the group consisting of

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], [[and]]

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide),

~~or a pharmaceutically acceptable salt~~ and pharmaceutically acceptable salts thereof.

46. (Currently amended) ~~[[A]]~~ The method according to claim 39 ~~any of the claims 39, 40, 41 or 42,~~ wherein the compound of component (i) is  
3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST]  
or a pharmaceutically acceptable salt thereof.

47. (Currently amended) ~~[[A]]~~ The method according to claim 39 ~~any of the claims 39, 40, 41 or 42,~~ wherein the compound of component (i) is  
3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide) or a pharmaceutically acceptable salt thereof.

48. (Currently amended) ~~[[A]]~~ The method according to claim 39 ~~any of the claims 39, 40, 41 or 42,~~ wherein the compound of component (i) is  
N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281] or a pharmaceutically acceptable salt thereof.

49. (Currently amended) [[A]] The method according to claim 39 ~~any of the claims 39, 40, 41 or 42~~, wherein the compound of component (i) is cis-4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast] or a pharmaceutically acceptable salt thereof.

50.-61. (Canceled)

62. (Currently amended) A treatment combination for neoplasms of lymphoid cells, comprising: therapeutically effective amounts of

(i) a compound selected from the group consisting of

N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide [INN: PICLAMILAST],

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide),

3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-isopropyl-3H-purine [Research Code: V-11294A],

N-[9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzo-diazepin-3(R)-yl]pyridine-4-carboxamide

[Research Code: CI-1018],

3,7-dihydro-3-(4-chlorophenyl)-1-propyl-1H-purine-2,6-dione

[INN: AROFYLLINE],

N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-

hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-

12-281],

N-(3,5-dichloropyridin-4-yl)-2-[5-fluoro-1-(4-

fluorobenzyl)-1H-indol-3-yl]-2-oxoacetamide [Research Code:

AWD-12-343],

Tetrahydro-5-[4-methoxy-3-[(1S,2S,4R)-2-

norbornyloxy]phenyl]-2(1H)-pyrimidone [INN: ATIZORAM];

β-[3-(cyclopentyloxy)-4-methoxyphenyl]-1,3-dihydro-1,3-

dioxo-2H-isoindole-2-propanamide [Research Code: CDC-801],

Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-urei-

dobenzo-furan-6-yl ester [INN: LIRIMILAST],

3,5-dichloro-4-[8-methoxy-2-(trifluoromethyl)quinolin-5-

ylcarbox-amido]pyridine-1-oxide [Research Code: SCH-

351591],

cis-4-cyano-4-[3-cyclopentyloxy-4-

methoxyphenyl]cyclohexane-1-carboxylic acid [INN:

Cilomilast],

~~the compounds~~ a compound with the research code [[codes]]  
CDC-998, D-4396, IC-485, CC-1088 or [[and]] KW4490,  
~~or a pharmaceutically acceptable salt~~ and pharmaceutically  
acceptable salts thereof,  
and (ii) one or more differentiation inducing agents and/or  
an agent effective in raising intracellular concentrations  
of cAMP or a stable analogue of cAMP.

63. (Currently amended) A treatment combination for  
neoplasms of lymphoid cells, comprising: therapeutically  
effective amounts of

(i) a compound selected from the group consisting of  
N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-  
methoxybenzamide [INN: PICLAMILAST],  
3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-  
dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-  
cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-  
pyrid-4-yl)-benzamide (Roflumilast-N-Oxide),  
3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-  
isopropyl-3H-purine [Research Code: V-11294A],  
N-[9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo[3,2,1-  
jk][1,4]benzo-diazepin-3(R)-yl]pyridine-4-carboxamide  
[Research Code: CI-1018],

3,7-dihydro-3-(4-chlorophenyl)-1-propyl-1H-purine-2,6-dione

[INN: AROFYLLINE],

N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-

hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281],

N-(3,5-dichloropyridin-4-yl)-2-[5-fluoro-1-(4-

fluorobenzyl)-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-343],

Tetrahydro-5-[4-methoxy-3-[(1S,2S,4R)-2-

norbornyloxy]phenyl]-2(1H)-pyrimidone [INN: ATIZORAM];

$\beta$ -[3-(cyclopentyloxy)-4-methoxyphenyl]-1,3-dihydro-1,3-

dioxo-2H-isoindole-2-propanamide [Research Code: CDC-801],

Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-urei-  
dobenzo-furan-6-yl ester [INN: LIRIMILAST],

3,5-dichloro-4-[8-methoxy-2-(trifluoromethyl)quinolin-5-  
ylcarbox-amido]pyridine-1-oxide [Research Code: SCH-351591],

cis-4-cyano-4-[3-cyclopentyloxy-4-

methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast],

~~the compounds~~ a compound with the research code [[codes]]

CDC-998, D-4396, IC-485, CC-1088 or [[and]] KW44907

~~or a pharmaceutically acceptable salt~~ and pharmaceutically acceptable salts thereof,

and (ii) one or more differentiation inducing agents.

64. (Currently amended) A treatment combination for neoplasms of lymphoid cells, comprising: therapeutically effective amounts of

(i) a compound selected from the group consisting of

N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-

methoxybenzamide [INN: PICLAMILAST],

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-

dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-

cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide),

3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-

isopropyl-3H-purine [Research Code: V-11294A],

N-[9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzo-diazepin-3(R)-yl]pyridine-4-carboxamide

[Research Code: CI-1018],

3,7-dihydro-3-(4-chlorophenyl)-1-propyl-1H-purine-2,6-dione

[INN: AROFYLLINE],

N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281],

N-(3,5-dichloropyridin-4-yl)-2-[5-fluoro-1-(4-fluorobenzyl)-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-343],

Tetrahydro-5-[4-methoxy-3-[(1S,2S,4R)-2-norbornyloxy]phenyl]-2(1H)-pyrimidone [INN: ATIZORAM];  
 $\beta$ -[3-(cyclopentyloxy)-4-methoxyphenyl]-1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanamide [Research Code: CDC-801],  
Methanesulfonic acid 2-(2,4-dichlorophenylcarbonyl)-3-ureidobenzo-furan-6-yl ester [INN: LIRIMILAST],  
3,5-dichloro-4-[8-methoxy-2-(trifluoromethyl)quinolin-5-ylcarbox-amido]pyridine-1-oxide [Research Code: SCH-351591],

cis-4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast],

~~the compounds~~ a compound with the research code [[codes]]

CDC-998, D-4396, IC-485, CC-1088 or [[and]] KW4490,

~~or a pharmaceutically acceptable salt~~ and pharmaceutically acceptable salts thereof,

and (ii) an agent effective in raising intracellular concentrations of cAMP or a stable analogue of cAMP.

65. (Currently amended) [[A]] The treatment combination according to claim 62 ~~any of the claims 62, 63 or 64,~~ wherein the compound of component (i) is selected from the group consisting of

N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281],

cis-4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast],

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], [[and]] 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide), ~~or a pharmaceutically acceptable salt~~ and pharmaceutically acceptable salts thereof.

66. (Currently amended) [[A]] The treatment combination according to claim 62 ~~any of the claims 62, 63 or 64,~~

wherein the compound of component (i) is selected from the group consisting of

3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], [[and]] 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide), ~~or a pharmaceutically acceptable salt~~ and pharmaceutically acceptable salts thereof.

67. (Currently amended) [[A]] The treatment combination according to claim 62 ~~any of the claims 62, 63 or 64,~~ wherein the compound of component (i) is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] or a pharmaceutically acceptable salt thereof.

68. (Currently amended) [[A]] The treatment combination according to claim 62 ~~any of the claims 62, 63 or 64,~~ wherein the compound of component (i) is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide) or a pharmaceutically acceptable salt thereof.

69. (Currently amended) [[A]] The treatment combination according to claim 62 ~~any of the claims 62, 63 or 64~~, wherein the compound of component (i) is N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide [Research Code: AWD-12-281] or a pharmaceutically acceptable salt thereof.

70. (Currently amended) [[A]] The treatment combination according to claim 62 ~~any of the claims 62, 63 or 64~~, wherein the compound of component (i) is cis-4-cyano-4-[3-cyclopentyloxy-4-methoxyphenyl]cyclohexane-1-carboxylic acid [INN: Cilomilast] or a pharmaceutically acceptable salt thereof.

71.-74. (Canceled)

75. (Currently amended) The method according to claim 40 ~~any of the claims 26, 27, 29, 30, 32, 33, 35, 36, 37, 38, 40, 41, 43, 44, 45, 46, 47, 48 or 49~~, wherein the differentiation inducing agent is selected from the group consisting of all trans retinoic acid, 13-cis-retinoic acid, CD437, rexinoids, histone deacetylase inhibitors, DNA methyltransferase inhibitors, hematopoietic growth factors,

interferon  $\alpha$ , interleukin 1, TRAIL, hexamethylene bisacetamide, cholecalciferol, arsenic trioxide, green tea catechin epigallocatechin-3-gallate, DNA topoisomerase II inhibitors, taraxinic acid, verticinone, PPAR-gamma agonists, antibodies versus CD19, CD20 or CD22, CD33-antibodies alone or as conjugate, alkylating cytostatika, purine analogs, cytosine- arabinosides, anticyclines, vinca-alkaloids and glucocorticosteroids.

76. (Currently amended) The method according to claim 40 ~~any of the claims 26, 27, 29, 30, 32, 33, 35, 36, 37, 38,~~  
~~40, 41, 43, 44, 45, 46, 47, 48 or 49,~~ wherein the differentiation inducing agent is a histone deacetylase inhibitor.

77. (Currently amended) The method according to claim 40 ~~any of the claims 26, 27, 29, 30, 32, 33, 35, 36, 37, 38,~~  
~~40, 41, 43, 44, 45, 46, 47, 48 or 49,~~ wherein the differentiation inducing agent is all trans retinoic acid.

78. (Currently amended) The method according to claim 40 ~~any of the claims 26, 27, 29, 30, 32, 33, 35, 36, 37, 38,~~  
~~40, 41, 43, 44, 45, 46, 47, 48 or 49,~~ wherein the agent

effective in raising intracellular concentrations of cAMP is selected from the group consisting of prostaglandin E2, prostacyclin derivatives, dopamine, dobutamine,  $\beta$ 2-adreno-receptor agonists, adenosine A1 receptor agonists, adenosine A2 receptor agonists and forskolin.

79. (Currently amended) A treatment combination according to claim 62 ~~any of the claims 50, 51, 53, 54, 55, 56, 58, 59, 60, 61, 62, 63, 65, 66, 67, 68, 69 or 70~~, wherein the differentiation inducing agent is selected from the group consisting of all trans retinoic acid, 13-cis-retinoic acid, CD437, rexinoids, histone deacetylase inhibitors, DNA methyltransferase inhibitors, hematopoietic growth factors, interferon  $\alpha$ , interleukin 1, TRAIL, hexamethylene bisacetamide, cholecalciferol, arsenic trioxide, green tea catechin epigallocatechin-3-gallate, DNA topoisomerase II inhibitors, taraxinic acid, verticinone, PPAR-gamma agonists, antibodies versus CD19, CD20 or CD22, CD33-antibodies alone or as conjugate, alkylating cytostatika, purine analogs, cytosine- arabinosides, anticyclines, vinca-alkaloids and glucocorticosteroids.

80. (Currently amended) A treatment combination according to claim 62 ~~any of the claims 50, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69 or 70~~, wherein the agent effective in raising intracellular concentrations of cAMP is selected from the group consisting of prostaglandin E2, prostacyclin derivatives, dopamine, dobutamine,  $\beta$ 2-adrenoreceptor agonists, adenosine A1 receptor agonists, adenosine A2 receptor agonists and forskolin.

81. (Currently amended) A treatment combination according to claim 62 ~~any of the claims 50, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69 or 70~~, wherein the differentiation inducing agent is a histone deacetylase inhibitor.

82. (Currently amended) A treatment combination according to claim 62 ~~any of the claims 50, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69 or 70~~, wherein the differentiation inducing agent is all trans retinoic acid.

83. (Canceled)

84. (Currently amended) The method according to claim 39  
~~any of the claims 25-49 and 75-78~~, wherein the neoplasm of  
lymphoid cells is leukemia.

85. (Currently amended) The treatment combination  
according to claim 62 ~~any of the claims 50-70 and 79-82~~,  
wherein the neoplasm of lymphoid cells is leukemia.